Return on investment of public health interventions: A systematic review

Journal of Epidemiology and Community Health

Volumn 71, Issue 8, 2017, Pages 827-834

  Masters, Rebecca ^a,b   Anwar, Elspeth ^b,c,d   Collins, Brendan ^b,d   Cookson, Richard ^e   Capewell, Simon ^b  

^a PUBLIC HEALTH WALES   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c HALTON BOROUGH COUNCIL   (United Kingdom)

^d Department of Public Health   (United Kingdom)

^e UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST-BENEFIT ANALYSIS; HEALTH SERVICES; INVESTMENT; LITERATURE REVIEW; PUBLIC HEALTH;

BUDGET; CINAHL; COST BENEFIT ANALYSIS; EMBASE; HIGH INCOME COUNTRY; HUMAN; INVESTMENT; MEDLINE; PUBLIC HEALTH; SCOPUS; SYSTEMATIC REVIEW; ECONOMICS; HEALTH PROMOTION;

SCOPUS;

HEALTH PROMOTION; PUBLIC HEALTH;

EID: 85022130419     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2016-208141     Document Type: Review

References (63)

1. British Medical Association. Local authorities plunder ring fenced public health funds. 2015. (cited 15 October 2015). http://www.bma.org.uk/news-views-analysis/news/2015/january/local-authoritiesplunder-ringfenced-public-health-funds
2. The Kings Fund. Cuts to public health spending: the falsest of false economies. 2015 (cited 12 February 2016). http://www.kingsfund.org.uk/blog/2015/08/cuts-public-health-spending-falsestfalse-economies
3. British Medical Journal. Raiding the public health budget. 2014. (cited October 2015). http://www.bmj.com/content/348/bmj.g2274
4. Hauck K, Smith P. Public choice analysis of public health priority setting. In: Cuyer A, ed. Encyclopaedia of health economics. Oxford, UK: Elsevier, 2014:184-93
5. Faculty of Public Health. What is Public Health [internet]. (cited 20 Jan 2017). http://www.fph.org.uk/what_is_public_health
6. National Institute for Clinical Excellence. Methods for the development of NICE public health guidance (third edition). Appendix I Quality appraisal checklist-economic evaluations. 2012. (cited 2 December 2015). https://www.nice.org.uk/article/pmg4/chapter/Appendix-I-Quality-appraisalchecklist-economic-evaluations
7. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161:749
8. Gould E. Childhood lead poisoning: conservative estimates of the social and economic benefits of lead hazard control. Environ Health Perspect 2009;117:1162-7
9. Peters JL, Anderson R. The cost-effectiveness of mandatory 20mph zones for the prevention of injuries. J Public Health (Oxf ) 2013;35:40-8
10. Abelson P, Taylor R, Butler J, et al. Returns on Investment in Public Health. Canberra: Department of Health and Ageing, 2003
11. Drummond M. Return on investment in needle and syringe programs in Australia: a summary report for the Commonwealth Department of Health and Ageing. Perth: Commonwealth of Australia, 2002
12. Evans-Lacko S, Henderson C, Thornicroft G, et al. Economic evaluation of the anti-sigma social marketing campaign in England 2009-2011. Br J Psychiatry 2013;55:95-101
13. Trust for America's Health. Prevention for a healthier America: investments in disease prevention yield substantial savings, stronger communities. Washington DC: Trust for America, 2008
14. McGuire A, Hughes D. The Economics of Family Planning Services: a report prepared for the Contraceptive Alliance. 1995. London: Family Planning Association
15. Gortmaker SL, Long MW, Resch SC, et al. Cost effectiveness of childhood obesity interventions: evidence and methods for CHOICES. Am J Prevent Med 2015;49:102-11
16. Miller TR, Zaloshnja E, Hendrie D. Cost-outcome analysis of booster seats for auto occupants aged 4 to 7 years. Pediatrics 2006;118:1994
17. Van Vonno CJ, Ozminkowski RJ, Smith MW, et al. What can a pilot congestive heart failure disease management program tell us about likely return on investment? A case study from a program offered to federal employees. Dis Manag 2005;8:346-60
18. Arrieta A, Woods JR, Qiao N, et al. Cost-benefit analysis of home blood pressure monitoring in hypertension diagnosis and treatment: an insurer perspective. Hypertension 2014;64:891-6
19. Steinbach R, Cairns J, Grundy C, et al. Cost benefit analysis of 20mph zones in London. 2012. Inj Prev 2013;19:211-13
20. Reynolds AJ, Temple JA, White BAB, et al. Age 26 cost-benefit analysis of the child-parent center early education program. Child Dev 2011;82:397404
21. Kleitz SJ, Borduin CM. Cost-benefit analysis of multisystematic therapy with serious and violent juvenile offenders. J Fam Psychol 2010;24:657-66
22. Nyman JA, Barleen NA, Abraham JM. The effectiveness of health promotion at the University of Minnesota: expenditures, absenteeism, and participation in specific programs. Am Coll Occup Environ Med 2010;52:269-80
23. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the NICE cost effectiveness threshold. Health Technol Assess 2015;19:1-203, iii-iv(cited 20 January 2017)
24. Glover D, Henderson J. Quantifying health impacts of government policies. London: Department of Health, 2010. (cited 20 January 2017) https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216003/dh_120108.pdf
25. Vos T, Carter R, Barendregt J, et al. Assessing Cost-Effectiveness in Prevention (ACE-Prevention): final report. Melbourne: University of Queensland, Brisbane and Deakin University, 2010
26. Matrix Evidence. Prioritising investments in public health. 2009. (cited 1 March 2016) http://help.matrixknowledge.com/
27. Owen L, Morgan A, Fischer A, et al. The costeffectiveness of public health interventions. J Public Health 2012;34:37-45
28. White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985;75:739-44
29. Creese A, Floyd K, Alban A, et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002;359:1635-42
30. Ding Y, Zangwill KM, Hay JW, et al. A cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol 2012;119:306-14
31. Andresen MA, Boyd N. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. Int J Drug Policy 2010;21:70-6
32. Boccalini S, Taddei C, Ceccherini V, et al. Economic analysis of the first 20 years of universal hepatitis vaccination program in Italy: an a posteriori evaluation and forecast of future benefits. Hum Vaccines Immunother 2013;9:51119-128
33. Garpenholt ö, Silfverdal S-A, Levin L-Å. Economic evaluation of general childhood vaccination against haemophilus influenza type b in Sweden. Scand J Infect Dis 1998;30:5-10
34. Holtgrave DR, Valdiserri RO, Gerber AR, et al. Human immunodeficiency virus counseling, testing, referral and partner notification services: a cost-benefit analysis. Arch Intern Med 1993;153:1225-30
35. Hutchinson AB, Farnham PG, Duffy N, et al. Return on public health investment: CDC's expanded HIV testing initiative. J Acquir Immune Defic Syndr 2012;59:281-6
36. Kwon JA, Anderson J, Kerr CC, et al. Estimating the cost-effectiveness of needle syringe programs in Australia. AIDS 2012;26:2201-10
37. Nguyen TQ, Weir BW, Des Jarlais DC, et al. Syringe exchange in the United States: a national level economic evaluation of hypothetical increases in investment. AIDS Behav 2014;18:2144-55
38. Zhou F, Bisgard KM, Yusuf HR, et al. Impact of universal haemophilus influenzae type B vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics 2002;110:653-61
39. Nelson W, Swint JM. Cost-benefit analysis of flouridation in Houston, Texas. J Public Health Dent 1976;36:88-95
40. Romano PS, Waitzman NJ, Scheffler RM, et al. Folic acid fortification of grain: an economic analysis. Am J Public Health 1995;85:667-76
41. Beard J, Rowell D, Scott D, et al. Economic analysis of a community-based falls prevention program. J R Inst Public Health 2006;120:742-51
42. Collins B. Cost effectiveness of stop smoking services in Wirral: 2015 update. UK: Wirral, 2015
43. Richard P, West K, Ku L. The return on investment of a Medicaid Tobacco Cessation Programme in Massachusetts. PLoS ONE 2012;7:e29665
44. Baker KM, Goetzel RZ, Pei X, et al. Using a return-on-investment estimation model to evaluate outcomes from an obesity management worksite health promotion program. J Occup Environ Med 2008;50:981-90
45. Goetzel RZ, Tabrizi M, Henke RM, et al. Estimating the return on investment from a health risk management program offered to small Colorado-based employers. J Occup Environ Med 2014;56:554-60
46. Kuehl KS, Elliot DL, Goldberg L, et al. Economic benefit of the PHLAME wellness programme on firefighter injury. Occup Med (Lond) 2013;63:203-9
47. Long DA, Sheehan P. A case study of population health improvement at a Midwest Regional Hospital Employer. Popul Health Manag 2010;13:72-7
48. Schwartz SM, Mason ST, Wang C, et al. Sustained economic value of a wellness and disease prevention program: an 8-year longitudinal evaluation. Popul Health Manag 2014;17:90-9
49. Windsor RA, Lowe JB, Perkins LL, et al. Health education for pregnant smokers: Its behavioural impact and cost benefit. Am J Public Health 1993; 83:201-6
50. Wang LY, Vernon-Smiley M, Gapinski MA, et al. Cost benefit study of school nursing services. JAMA Pediatr 2013;5441:642-8
51. Ozminkowski RJ, Dunn RL, Goetzel RZ, et al. A return on investment evaluation of the Citibank, N.A, Health Management Program. Am J Health Promot 1999;14:31-43
52. Moore JM, Shartle D, Faudskar L, et al. Impact of a patient-centred pharmacy program and intervention in a high-risk group. J Manag Care Pharm 2013;19:228-36
53. Rundell OH, Paredes A. Benefit-cost methodology in the evaluation of therapeutic services for alcoholism. Alcohol Clin Exp Res 1979;3:324-33
54. Spence MM, Makerem AF, Reyes SL, et al. Evaluation of an outpatient pharmacy clinical services program on adherence and clinical outcomes among patients with diabetes and/or coronary artery disease. J Manag Care Speciality Pharm 2014;20:1036-45
55. Lokkerbol J, Adema D, Cuijpers P, et al. Improving the cost-effectiveness of a healthcare system for depressive disorders by implementing telemedicine: a health economic modelling study. Am J Geriatr Psychiatry 2014;22:253-62
56. Schweinhart LJ, Montie J, Xiang Z, et al. Lifetime effects: the HighScope Perry Preschool study through age 40. (Monographs of the HighScope Educational Research Foundation, 14). Ypsilanti, MI: HighScope Press, 2005
57. Dopp AR, Borduin CM, Wagner DV, et al. The economic impact of multisystemic therapy through midlife: a cost-benefit analysis with serious juvenile offenders and their siblings. J Couns Clin Psychol 2014;82:694-705
58. Bonin EM, Stevens M, Beecham J, et al. Costs and longer-term savings of parenting programmes for the prevention of persistent conduct disorder: a modelling study. BMC Public Health 2011;11:803
59. Guo JY, Gandavarapu S. An economic evaluation of health-promotive built environment changes. Prev Med 2010;50:44-9
60. Medivil J, Garcia-Altes A, Perez K, et al. Speed cameras in an urban setting: a cost-benefit analysis. Inj Prev 2012;18:75-80
61. Wang G, Macera CA, Scudder-Soucie B, et al. A cost benefit analysis of physical activity using bike/pedestrian trails. Health Promot Pract 2005;6:174
62. Drummond M, Brandt A, Luce B, et al. Standardizing methodologies for economic evaluation in health care: practice, problems, and potential. Int J Technol Assess Health Care 1993;9:26-36
63. Capewell S, O'Flaherty M. Mortality falls can rapidly follow population-wide risk factor changes. Lancet 2011;378:752-3